Caroline Kistorp

List of Publications by Year
in descending order

81	3,467	257101 24	149479 56
papers	citations	h-index	g-index

81	81	81	5040
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. Circulation: Heart Failure, 2022, 15, .	1.6	17
2	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular Diabetology, 2022, 21, 34.	2.7	10
3	Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study). BMC Geriatrics, 2022, 22, 230.	1.1	1
4	Sodiumâ€Glucose Cotransporterâ€2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	1.2	1
5	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. American Heart Journal, 2022, 250, 57-57.	1.2	1
6	The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 196-203.	0.3	6
7	Effect of Anabolicâ€“Androgenic Steroid Abuse on the Contact Activation System. Thrombosis and Haemostasis, 2021, 121, 1268-1273.	1.8	4
8	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 106-116.	5.5	80
9	Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2664-e2672.	1.8	13
10	Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 948-961.	2.0	5
11	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation, 2021, 143, 2208-2210.	1.6	8
12	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 836.	3.0	95
13	Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Lowâ€Risk Population With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020395.	1.6	9
14	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. Journal of the American Heart Association, 2021, 10, e020418.	1.6	12
15	Mineralocorticoid Receptor Antagonist Improves Cardiac Structure inÂType 2ÂDiabetes. JACC: Heart Failure, 2021, 9, 550-558.	1.9	14
16	Anabolicâ€“Androgenic Steroid Abuse Impairs Fibrin Clot Lysis. Seminars in Thrombosis and Hemostasis, 2021, 47, 011-017.	1.5	6
17	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	0.7	6
18	Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?. European Heart Journal, 2020, 41, 1346-1353.	1.0	45

#	Article	IF	Citations
19	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovascular Diabetology, 2020, 19, 180.	2.7	7
20	Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. Diabetes and Metabolism, 2020, 47, 101190.	1.4	15
21	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. American Heart Journal, 2020, 228, 47-56.	1.2	61
22	Effect of Empagliflozin on Hemodynamics in Patients WithÂHeartÂFailure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 2740-2751.	1.2	57
23	Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity. Journal of the Endocrine Society, 2020, 4, bvaa050.	0.1	12
24	Letter to the Editor: â€œRate and Extent of Recovery from Reproductive and Cardiac Dysfunction Due to Androgen Abuse in Menâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3028-e3029.	1.8	1
25	Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Biomarkers, 2020, 25, 248-259.	0.9	2
26	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	2.2	16
27	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and endâ€stage renal disease. European Journal of Heart Failure, 2020, 22, 813-820.	2.9	6
28	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	0.4	10
29	Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study. Global Heart, 2020, 15, 25.	0.9	3
30	Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation. ESC Heart Failure, 2019, 6, 983-991.	1.4	21
31	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials, 2019, 20, 374.	0.7	35
32	Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, doubleâ€blind, placeboâ€controlled trial (MIRAD trial). Diabetes, Obesity and Metabolism, 2019, 21, 2305-2314.	2.2	13
33	Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study. Open Heart, 2019, 6, e000840.	0.9	11
34	Association Between 3-Iodothyronamine (T1<scp>am</scp>) Concentrations and Left Ventricular Function in Chronic Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1232-1238.	1.8	10
35	Prevalence of heart failure and the diagnostic value of MRâ€proANP in outpatients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 736-740.	2.2	16
36	Metabolic consequences of gonadotropinâ€releasing hormone agonists vs orchiectomy: a randomized clinical study. BJU International, 2019, 123, 602-611.	1.3	29

#	Article	IF	Citations
37	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	1.4	18
38	MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail. Journal of the Endocrine Society, 2019, 3, .	0.1	0
39	Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers. Thrombosis and Haemostasis, 2018, 47, 647-653.	1.8	13
40	Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocrine Connections, 2018, 7, 115-123.	0.8	21
41	Quantification of visceral adipose tissue in polycystic ovary syndrome: dual-energy X-ray absorptiometry versus magnetic resonance imaging. Acta Radiologica, 2018, 59, 13-17.	0.5	14
42	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: <scp>A</scp> randomized clinical trial. Diabetes, Obesity and Metabolism, 2018, 20, 215-218.	2.2	108
43	Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study. European Journal of Endocrinology, 2018, 178, 65-74.	1.9	18
44	Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids. Journal of Hypertension, 2018, 36, 277-285.	0.3	49
45	Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. American Heart Journal, 2018, 203, 49-56.	1.2	40
46	Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2182-2188.	1.8	98
47	Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. Hormone and Metabolic Research, 2017, 49, 411-417.	0.7	21
48	Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clinical Endocrinology, 2017, 87, 249-256.	1.2	33
49	Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive BioMedicine Online, 2017, 35, 121-127.	1.1	63
50	Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. Journal of Urology, 2017, 197, 1441-1447.	0.2	24
51	Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovascular Disorders, 2017, 17, 22.	0.7	9
52	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)â€”a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	2.9	343
53	Evaluation of ICD-10 algorithms to identify hypopituitary patients in the Danish National Patient Registry. Clinical Epidemiology, 2017, Volume 9, 75-82.	1.5	2
54	Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS ONE, 2016, 11, e0161208.	1.1	108

#	Article	IF	Citations
55	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovascular Disorders, 2016, 16, 117.	0.7	21
56	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	5.5	159
57	Cardiomyocyte Expression and Cell-specific Processing of Procholecystokinin. Journal of Biological Chemistry, 2015, 290, 6837-6843.	1.6	24
58	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. International Journal of Cardiology, 2015, 195, 143-148.	0.8	20
59	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. Journal of Cardiac Failure, 2015, 21, 250-257.	0.7	5
60	Longâ€term Lâ€Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, doubleâ€blind, crossâ€over, placeboâ€controlled intervention study. Clinical Endocrinology, 2015, 83, 931-937.	1.2	38
61	Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. BMC Obesity, 2014, 1, 24.	3.1	21
62	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	22
63	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: A prospective study. Metabolism: Clinical and Experimental, 2014, 63, 141-149.	1.5	24
64	Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine, 2013, 43, 626-634.	1.1	86
65	Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. BMC Cardiovascular Disorders, 2013, 13, 80.	0.7	22
66	Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. European Journal of Preventive Cardiology, 2012, 19, 999-1004.	0.8	13
67	Î±â€Defensins and outcome in patients with chronic heart failure. European Journal of Heart Failure, 2012, 14, 387-394.	2.9	22
68	Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population. Inflammation Research, 2010, 59, 503-510.	1.6	11
69	Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure. Scandinavian Cardiovascular Journal, 2010, 44, 260-266.	0.4	14
70	Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. International Journal of Cardiology, 2010, 143, 35-42.	0.8	73
71	Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scandinavian Cardiovascular Journal, 2010, 44, 92-99.	0.4	24
72	IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. European Journal of Endocrinology, 2009, 160, 25-31.	1.9	103

#	Article	IF	Citations
73	Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. European Journal of Heart Failure, 2008, 10, 380-387.	2.9	26
74	N-Terminal-Pro-B-type Natriuretic Peptide in Acute Hyperthyroidism. Thyroid, 2007, 17, 237-241.	2.4	8
75	Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: The Frederiksberg heart failure study. International Journal of Cardiology, 2007, 119, 80-82.	0.8	13
76	N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clinical Endocrinology, 2007, 66, 619-625.	1.2	16
77	Risk Stratification in Secondary Prevention. Circulation, 2006, 114, 184-186.	1.6	13
78	Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure. Circulation, 2005, 112, 1756-1762.	1.6	554
79	N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults. JAMA - Journal of the American Medical Association, 2005, 293, 1609.	3.8	463
80	Biochemical Cardiac Risk Markers in the General Population, Hypertension and Coronary Artery Disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 138-142.	0.6	5
81	Prevalence and characteristics of diabetic patients in a chronic heart failure population. International Journal of Cardiology, 2005, 100, 281-287.	0.8	27